Epilepsy CurrentsLamotrigine in Epilepsy: Safe for the Heart after All?

Two major studies involving more than 200,000 patients with epilepsy found lamotrigine does not increase risk of ventricular arrhythmias or sudden cardiac death compared to levetiracetam. This directly challenges the FDA’s 2020 safety warning that raised concerns about cardiac risks, providing reassurance for continued clinical use of this widely prescribed antiseizure medication.

💊 KEY CLINICAL CONSIDERATIONS

• Lamotrigine showed no increased cardiac risk across diverse populations (Medicare and UK datasets) with hazard ratios of 0.73-0.84 for ventricular arrhythmias—actually trending toward protective effect rather than harm
• Patients with pre-existing cardiac disease showed reduced arrhythmia risk on lamotrigine (HR 0.51 in those with baseline arrhythmias, HR 0.67 in antiarrhythmic drug users), contradicting expectations that vulnerable populations would fare worse
• Two-year absolute arrhythmia risk remained low across both medications (1.7-2.3% in Medicare, 0.2-0.3% in UK cohort), with lamotrigine users demonstrating lower all-cause mortality potentially due to better medication adherence
• Study limitations include reliance on administrative data capturing only hospital-presenting arrhythmias, missing out-of-hospital sudden deaths, and limited long-term follow-up beyond 2 years

🎯 PRACTICE APPLICATIONS

• Continue prescribing lamotrigine as first-line option for appropriate seizure syndromes without heightened cardiac concern, particularly for women of childbearing potential where pregnancy safety data remains favorable
• Document baseline ECG in patients with known structural heart disease or those on concurrent QT-prolonging medications, but recognize cardiac screening is not mandatory for routine lamotrigine initiation
• Counsel patients that recent large-scale evidence does not support cardiac safety concerns, addressing anxiety from 2020 FDA warning while maintaining awareness of concurrent sodium channel blockers
• Monitor appropriately without excessive cardiac workup—reserve repeat ECGs for patients developing cardiac symptoms rather than routine surveillance in asymptomatic individuals

More in Antiseizure Medications